ゲノムバイオマーカーの世界市場レポート 2025年

ゲノムバイオマーカーの市場規模は今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）17.3%で165億1,000万米ドルに成長します。予測期間の成長は、卵巣がんや胃がんの症例数の増加、遺伝子検査の受け入れと認知度の向上、がんの診断と治療におけるゲノムバイオマーカーの使用の増加、がん患者の増加、コンパニオン診断の採用の増加に起因すると考えられます。予測期間における主な動向としては、次世代シーケンシング（NGS）、他のオミックスとの統合、ゲノム技術の進歩、製品イノベーション、先進ヘルスケアサービスなどが挙げられます。

個別化医療に対する需要の高まりは、ゲノムバイオマーカー市場の拡大を牽引すると予測されます。個別化医療（精密医療）とは、主に患者の遺伝子やゲノム情報に基づいて、ヘルスケアに関する意思決定や治療を患者一人ひとりの特徴に合わせて調整することです。この需要に拍車をかけているのは、患者中心のケアへの注目の高まり、遺伝子シークエンシングと解析の進歩、患者中心のアプローチへのシフト、患者データを管理するための電子カルテ（EHR）の活用といった要因です。ゲノムバイオマーカーは、ヘルスケアプロバイダーが個人の特定の遺伝子プロファイルに従って治療をカスタマイズし、それによって治療効果を最適化し、副作用を減らすことを可能にするため、個別化医療において不可欠です。例えば、個別化医療連合（Personalized Medicine Coalition）は、2022年に12種類の個別化治療薬が新たに承認されたと報告しており、これは新たに承認された治療薬全体の約34%に相当し、以前に比べて34%増加しています。このように、個別化医療に対する需要の高まりは、ゲノムバイオマーカー市場の成長を加速させると予想されます。

ゲノムバイオマーカー市場の主なプレーヤーは、肺がんの特定の遺伝子変異の検出を強化し、診断精度を向上させ、高度なゲノム技術を通じて個別化治療戦略をサポートするために、肺試薬などの先進製品の開発に注力しています。肺試薬は、肺疾患の診断検査や研究に使用される特殊な物質で、がんの遺伝子プロファイルに基づいて治療を誘導することで、精密医療を促進します。例えば、2023年12月、先進ゲノムアッセイと精密診断を専門とする英国のBiofidelity社は、ASPYRE-Lung試薬を発表しました。これらの試薬は、肺がんにおける重大な遺伝子変異や変化を検出するように設計されており、標的治療や個別化治療計画を指示するために極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ゲノムバイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のゲノムバイオマーカー市場：成長率分析
• 世界のゲノムバイオマーカー市場の実績：規模と成長, 2019-2024
• 世界のゲノムバイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界ゲノムバイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のゲノムバイオマーカー市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予測バイオマーカー
• 予後バイオマーカー
• 世界のゲノムバイオマーカー市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 心血管疾患
• 神経疾患
• 腎疾患
• その他の疾患の適応症
• 世界のゲノムバイオマーカー市場検証によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 分析検証
• 臨床検証
• 臨床的有用性
• 世界のゲノムバイオマーカー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断センター
• その他のエンドユーザー
• 世界のゲノムバイオマーカー市場予測バイオマーカーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物反応バイオマーカー
• コンパニオン診断バイオマーカー
• 薬力学的バイオマーカー
• 疾患感受性を予測する遺伝子マーカー
• 世界のゲノムバイオマーカー市場予後バイオマーカーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん予後バイオマーカー
• 心血管疾患の予後バイオマーカー
• 神経変性疾患の予後バイオマーカー
• 感染症予後バイオマーカー

第7章 地域別・国別分析

• 世界のゲノムバイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のゲノムバイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ゲノムバイオマーカー市場：競合情勢
• ゲノムバイオマーカー市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Diagnostics International Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • PerkinElmer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Almac Group Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Azenta Inc.
• Novogene Corporation
• Oxford Nanopore Technologies Ltd.
• Celerion
• Quanterix Corporation
• Bio-Rad Laboratories Inc.
• NantHealth Inc.
• Centogene N.V.
• Sophia Genetics SA
• Envisagenics
• Deep Genomics
• Creative Diagnostics
• Macrogen Inc.
• Guardant Health Inc.
• Sema4

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ゲノムバイオマーカー市場2029：新たな機会を提供する国
• ゲノムバイオマーカー市場2029：新たな機会を提供するセグメント
• ゲノムバイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Genomic biomarkers are specific sequences or variations in DNA or RNA that provide insights into biological processes, conditions, or responses to treatments. In precision medicine, these biomarkers help predict disease risk, diagnose conditions, monitor disease progression, or guide treatment decisions. They are essential for personalized medicine, enabling healthcare providers to tailor treatments based on an individual's genetic makeup, thereby enhancing therapy effectiveness and minimizing adverse effects.

The main types of genomic biomarkers are predictive biomarkers and prognostic biomarkers. Predictive biomarkers are biological molecules found in blood, other body fluids, or tissues that indicate whether a patient is likely to benefit from a specific medical treatment or intervention. They are relevant for various disease indications, including oncology, cardiovascular diseases, neurological diseases, renal disorders, and others, and are validated through analytical, clinical, and clinical utility validations. These biomarkers are utilized by end-users such as hospitals, diagnostic centers, and other healthcare providers.

The genomic biomarkers market research report is one of a series of new reports from The Business Research Company that provides genomic biomarkers market statistics, including genomic biomarkers industry global market size, regional shares, competitors with a genomic biomarkers market share, detailed genomic biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the genomic biomarkers industry. This genomic biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genomic biomarkers market size has grown rapidly in recent years. It will grow from $7.42 $ billion in 2024 to $8.72 $ billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to the rising emphasis on various genetic testing activities, growing cases of chronic diseases, growing emphasis on precision medicine initiatives, growing adoption of companion diagnostics, and rising number of patients with neurological diseases.

The genomic biomarkers market size is expected to see rapid growth in the next few years. It will grow to $16.51 $ billion in 2029 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to the increasing number of ovarian and gastric cancer cases, growing acceptance and awareness of genetic testing, increasing use of genomic biomarkers in cancer diagnosis and treatment, increasing number of cancer patients, and growing adoption of companion diagnostics. Major trends in the forecast period include next-generation sequencing (NGS), integration with other omics, genomic technological advancements, product innovations, and advanced healthcare services.

The growing demand for personalized medicine is projected to drive the expansion of the genomic biomarkers market. Personalized medicine, or precision medicine, tailors healthcare decisions and treatments to the unique characteristics of each patient, primarily based on their genetic and genomic information. This demand is fueled by factors such as increased focus on patient-centered care, advancements in genetic sequencing and analysis, the shift towards a patient-centric approach, and the utilization of electronic health records (EHRs) for managing patient data. Genomic biomarkers are essential in personalized medicine as they enable healthcare providers to customize medical treatments according to an individual's specific genetic profile, thereby optimizing treatment effectiveness and reducing side effects. For instance, the Personalized Medicine Coalition reported in 2022 that 12 new personalized medications were approved, representing approximately 34% of all newly approved treatments and a 34% increase over previous years. As such, the rising demand for personalized medicine is expected to accelerate growth in the genomic biomarkers market.

Key players in the genomic biomarkers market are concentrating on developing advanced products, such as lung reagents, to enhance the detection of specific genetic mutations in lung cancer, improve diagnostic accuracy, and support personalized treatment strategies through advanced genomic technologies. Lung reagents are specialized substances used in diagnostic tests and research related to lung conditions, facilitating precision medicine by guiding treatment based on the genetic profile of the cancer. For example, in December 2023, Biofidelity, a UK-based company specializing in advanced genomic assays and precision diagnostics, introduced ASPYRE-Lung reagents. These reagents are designed to detect significant genetic mutations and alterations in lung cancer, crucial for directing targeted therapies and personalized treatment plans.

In November 2022, Biocare Medical, a US-based manufacturer of immunohistochemistry (IHC) and molecular pathology products for cancer and infectious disease diagnostics, acquired Empire Genomics LLC for an undisclosed amount. This acquisition is intended to enhance Biocare Medical's capabilities in precision diagnostics and molecular pathology. Empire Genomics LLC, also based in the US, produces genomic biomarkers used in cancer diagnosis and personalized medicine.

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

North America was the largest region in the genomic biomarkers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the genomic biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genomic biomarkers market consists of sales of genomic biomarker panels, real-time PCR detection systems, and droplet digital PCR (ddPCR) systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Genomic Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on genomic biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for genomic biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genomic biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Predictive Biomarkers; Prognostic Biomarkers
• 2) By Disease Indication: Oncology; Cardiovascular Diseases; Neurological Diseases; Renal Disorders; Other Disease Indications
• 3) By Validation: Analytical Validation; Clinical Validation; Clinical Utility
• 4) By End-User: Hospitals; Diagnostic Centers; Other End User
• Subsegments:
• 1) By Predictive Biomarkers: Drug Response Biomarkers; Companion Diagnostics Biomarkers; Pharmacodynamic Biomarkers; Predictive Genetic Markers for Disease Susceptibility
• 2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers; Cardiovascular Disease Prognostic Biomarkers; Neurodegenerative Disease Prognostic Biomarkers; Infectious Disease Prognostic Biomarkers
• Companies Mentioned: Thermo Fisher Scientific Inc.; Roche Diagnostics International Ltd.; Illumina Inc.; PerkinElmer Inc.; Almac Group
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Genomic Biomarkers Market Characteristics

3. Genomic Biomarkers Market Trends And Strategies

4. Genomic Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Genomic Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Genomic Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Genomic Biomarkers Market Growth Rate Analysis
• 5.4. Global Genomic Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Genomic Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Genomic Biomarkers Total Addressable Market (TAM)

6. Genomic Biomarkers Market Segmentation

• 6.1. Global Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Predictive Biomarkers
• Prognostic Biomarkers
• 6.2. Global Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Renal Disorders
• Other Disease Indications
• 6.3. Global Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analytical Validation
• Clinical Validation
• Clinical Utility
• 6.4. Global Genomic Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Other End User
• 6.5. Global Genomic Biomarkers Market, Sub-Segmentation Of Predictive Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Response Biomarkers
• Companion Diagnostics Biomarkers
• Pharmacodynamic Biomarkers
• Predictive Genetic Markers for Disease Susceptibility
• 6.6. Global Genomic Biomarkers Market, Sub-Segmentation Of Prognostic Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Prognostic Biomarkers
• Cardiovascular Disease Prognostic Biomarkers
• Neurodegenerative Disease Prognostic Biomarkers
• Infectious Disease Prognostic Biomarkers

7. Genomic Biomarkers Market Regional And Country Analysis

• 7.1. Global Genomic Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Genomic Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Genomic Biomarkers Market

• 8.1. Asia-Pacific Genomic Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Genomic Biomarkers Market

• 9.1. China Genomic Biomarkers Market Overview
• 9.2. China Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Genomic Biomarkers Market

• 10.1. India Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Genomic Biomarkers Market

• 11.1. Japan Genomic Biomarkers Market Overview
• 11.2. Japan Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Genomic Biomarkers Market

• 12.1. Australia Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Genomic Biomarkers Market

• 13.1. Indonesia Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Genomic Biomarkers Market

• 14.1. South Korea Genomic Biomarkers Market Overview
• 14.2. South Korea Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Genomic Biomarkers Market

• 15.1. Western Europe Genomic Biomarkers Market Overview
• 15.2. Western Europe Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Genomic Biomarkers Market

• 16.1. UK Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Genomic Biomarkers Market

• 17.1. Germany Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Genomic Biomarkers Market

• 18.1. France Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Genomic Biomarkers Market

• 19.1. Italy Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Genomic Biomarkers Market

• 20.1. Spain Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Genomic Biomarkers Market

• 21.1. Eastern Europe Genomic Biomarkers Market Overview
• 21.2. Eastern Europe Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Genomic Biomarkers Market

• 22.1. Russia Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Genomic Biomarkers Market

• 23.1. North America Genomic Biomarkers Market Overview
• 23.2. North America Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Genomic Biomarkers Market

• 24.1. USA Genomic Biomarkers Market Overview
• 24.2. USA Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Genomic Biomarkers Market

• 25.1. Canada Genomic Biomarkers Market Overview
• 25.2. Canada Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Genomic Biomarkers Market

• 26.1. South America Genomic Biomarkers Market Overview
• 26.2. South America Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Genomic Biomarkers Market

• 27.1. Brazil Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Genomic Biomarkers Market

• 28.1. Middle East Genomic Biomarkers Market Overview
• 28.2. Middle East Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Genomic Biomarkers Market

• 29.1. Africa Genomic Biomarkers Market Overview
• 29.2. Africa Genomic Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Genomic Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Genomic Biomarkers Market, Segmentation By Validation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Genomic Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Genomic Biomarkers Market Competitive Landscape
• 30.2. Genomic Biomarkers Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Diagnostics International Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. PerkinElmer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Almac Group Overview, Products and Services, Strategy and Financial Analysis

31. Genomic Biomarkers Market Other Major And Innovative Companies

• 31.1. Azenta Inc.
• 31.2. Novogene Corporation
• 31.3. Oxford Nanopore Technologies Ltd.
• 31.4. Celerion
• 31.5. Quanterix Corporation
• 31.6. Bio-Rad Laboratories Inc.
• 31.7. NantHealth Inc.
• 31.8. Centogene N.V.
• 31.9. Sophia Genetics SA
• 31.10. Envisagenics
• 31.11. Deep Genomics
• 31.12. Creative Diagnostics
• 31.13. Macrogen Inc.
• 31.14. Guardant Health Inc.
• 31.15. Sema4

32. Global Genomic Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Genomic Biomarkers Market

34. Recent Developments In The Genomic Biomarkers Market

35. Genomic Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Genomic Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Genomic Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Genomic Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer